ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBRX ImmunityBio, Inc.

未开盘 09-03 16:00:00 EDT

8.19

+0.24

+3.02%

盘后8.17

-0.02-0.29%

19:57 EDT

最高8.21	最低7.88	成交量527.18万
今开8.00	昨收7.95	日振幅4.15%
总市值86.80亿	流通市值33.33亿	总股本10.60亿
成交额4,248万	换手率1.30%	流通股本4.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBRX","market":"US","secType":"STK","nameCN":"ImmunityBio, Inc.","latestPrice":8.19,"timestamp":1788465600000,"preClose":7.95,"halted":0,"volume":5271763,"hourTrading":{"tag":"盘后","latestPrice":8.166,"preClose":8.19,"latestTime":"19:57 EDT","volume":213353,"amount":1745235.0315,"timestamp":1788479845850,"change":-0.024,"changeRate":-0.00293,"amplitude":0.01221},"delay":0,"changeRate":0.030188679245282932,"floatShares":407000000,"shares":1059836273,"eps":-0.988661,"marketStatus":"未开盘","change":0.24,"latestTime":"09-03 16:00:00 EDT","open":8,"high":8.21,"low":7.88,"amount":42479180.92481,"amplitude":0.041509,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.988661,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788508800000},"marketStatusCode":0,"adr":0,"listingDate":1438056000000,"exchange":"NASDAQ","adjPreClose":7.95,"preHourTrading":{"tag":"盘前","latestPrice":8,"preClose":7.95,"latestTime":"09:29 EDT","volume":37815,"amount":302792.72178,"timestamp":1788442170095,"change":0.05,"changeRate":0.006289,"amplitude":0.020591},"postHourTrading":{"tag":"盘后","latestPrice":8.166,"preClose":8.19,"latestTime":"19:57 EDT","volume":213353,"amount":1745235.0315,"timestamp":1788479845850,"change":-0.024,"changeRate":-0.00293,"amplitude":0.01221},"volumeRatio":0.644988,"impliedVol":0.7788,"impliedVolPercentile":0.1349},"requestUrl":"/m/hq/s/IBRX","defaultTab":"news","newsList":[{"id":"1148284703","title":"前世界银行行长金墉博士加盟ImmunityBio，出任副董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=1148284703","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148284703?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:01","pubTimestamp":1786366871,"startTime":"0","endTime":"0","summary":"ImmunityBio宣布，已任命前世界银行行长、全球卫生领域领军人物金墉博士（DR. Jim Yong Kim）为副董事长。这位医卫界翘楚的加入，将为这家生物科技公司注入新的战略视野。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172849778","title":"异动解读｜ImmunityBio盘中下跌5.02%，报7.665美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172849778","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172849778?lang=zh_cn&edition=full","pubTime":"2026-07-23 00:27","pubTimestamp":1784737658,"startTime":"0","endTime":"0","summary":"7月23日，ImmunityBio盘中下跌5.02%，报7.665美元/股，成交额2621.54万美元。ImmunityBio所在的生物科技行业中，个股中，Lakewood-Amedex Biotherapeutics涨87.1%，Arrowhead Research Corporation涨21.42%，吉利德科学涨0.7%，艾伯维公司跌0.17%，Ionis Pharmaceuticals跌0.45%。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。核心产品Anktiva已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108961094","title":"异动解读｜ImmunityBio盘中上涨5.34%，报7.865美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108961094","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108961094?lang=zh_cn&edition=full","pubTime":"2026-07-21 22:36","pubTimestamp":1784644578,"startTime":"0","endTime":"0","summary":"7月21日，ImmunityBio盘中上涨5.34%，报7.865美元/股，成交额1368.51万美元。ImmunityBio所在的生物科技行业中，个股中，吉利德科学跌1.0%，艾伯维公司涨0.86%，安进涨0.7%，Argenx SE涨3.18%，福泰制药涨0.3%。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。核心产品Anktiva已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126309769","title":"异动解读｜ImmunityBio盘中下跌5.11%，生物医药板块获利了结延续资金轮动压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1126309769","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126309769?lang=zh_cn&edition=full","pubTime":"2026-07-17 02:17","pubTimestamp":1784225847,"startTime":"0","endTime":"0","summary":"7月17日，ImmunityBio盘中下跌5.11%，报7.335美元/股，成交额3217.43万美元。消息面上，美股生物医药板块在过去一个月累计上涨约25%后持续承压，资金从高贝塔小盘生物科技股向大市值防御型药企的结构性轮动仍在延续。ImmunityBio作为年内涨幅较大的小盘标的，在无新增基本面利空的情况下连续回撤，系板块集中获利了结的缩影。ImmunityBio是一家综合性免疫治疗公司，核心产品Anktiva已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143053323","title":"异动解读｜ImmunityBio盘中下跌5.17%，生物医药板块集中获利了结引发回撤","url":"https://stock-news.laohu8.com/highlight/detail?id=1143053323","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143053323?lang=zh_cn&edition=full","pubTime":"2026-07-14 00:27","pubTimestamp":1783960045,"startTime":"0","endTime":"0","summary":"7月14日，ImmunityBio盘中下跌5.17%，报7.795美元/股，成交额4432.7万美元。消息面上，美股生物医药板块在过去一个月累计上涨约25%后，因集中获利了结引发急跌，高贝塔代表性ETF此前单日大跌4%。ImmunityBio作为年内涨幅较大的小盘生物科技股，在无基本面利空的情况下持续回撤，资金呈现从高风险小盘股向强防御大市值药企的结构性轮动态势。ImmunityBio是一家综合性免疫治疗公司，核心产品Anktiva已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650155620","title":"1个月上涨25%后，美国生物医药板块周五重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2650155620","media":"华尔街见闻","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650155620?lang=zh_cn&edition=full","pubTime":"2026-07-11 15:10","pubTimestamp":1783753844,"startTime":"0","endTime":"0","summary":"美股生物医药板块因集中获利了结引发急跌，高贝塔代表性ETF（XBI）单日大跌4%。Moderna、ImmunityBio等年内暴涨股在无基本面利空的情况下回撤8%~11%，资金呈现从高风险小盘股向强防御大市值药企跨板块结构性轮动。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3776698","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"1个月上涨25%后，美国生物医药板块周五重挫","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLYZ","MRNX","BK4588","BK4581","LLYX","MRNY","ELIL","161726","LLY","BK4585","XBI","LLII","ELIS","IBRX","MRNA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1123783820","title":"异动解读｜ImmunityBio盘中下跌5.58%，报8.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123783820","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123783820?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:44","pubTimestamp":1783691071,"startTime":"0","endTime":"0","summary":"7月10日，ImmunityBio盘中下跌5.58%，报8.34美元/股，成交额1095.16万美元。ImmunityBio所在的生物科技行业中，个股普遍承压，其中Moderna跌7.43%，Ionis Pharmaceuticals跌7.16%，Argenx SE跌2.51%，艾伯维公司跌0.08%，阿尔尼拉姆制药公司涨0.58%。ImmunityBio是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，核心产品Anktiva已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102150950","title":"异动解读｜ImmunityBio盘中下跌5.05%，报8.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102150950","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102150950?lang=zh_cn&edition=full","pubTime":"2026-07-07 23:04","pubTimestamp":1783436652,"startTime":"0","endTime":"0","summary":"7月7日，ImmunityBio盘中下跌5.05%，报8.46美元/股，成交额3433.76万美元。ImmunityBio所在的生物科技行业中，个股涨跌不一，其中吉利德科学涨4.36%，艾伯维公司涨1.21%，Moderna跌3.55%，福泰制药跌1.66%，Natera跌0.85%。ImmunityBio是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，核心产品Anktiva®已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128201329","title":"异动解读｜ImmunityBio盘中下跌5.16%，报8.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1128201329","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128201329?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:24","pubTimestamp":1783347861,"startTime":"0","endTime":"0","summary":"7月6日，ImmunityBio盘中下跌5.16%，报8.77美元/股，成交额3548.56万美元。ImmunityBio所在的生物科技行业中，个股普遍承压，其中吉利德科学跌2.22%，艾伯维公司跌1.80%，Moderna涨1.04%，安进跌3.25%，福泰制药跌2.07%。ImmunityBio是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，核心产品Anktiva®已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118809771","title":"异动解读｜ImmunityBio盘中上涨5.65%，FDA警告信抛压消化后盘中反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1118809771","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118809771?lang=zh_cn&edition=full","pubTime":"2026-06-17 23:19","pubTimestamp":1781709590,"startTime":"0","endTime":"0","summary":"6月17日，ImmunityBio盘中上涨5.65%，报7.115美元/股，成交额3261.63万美元。此前该股因FDA处方药推广办公室就核心药物Anktiva营销合规问题发出正式警告信，盘中一度承压下挫。消息面上，公司已于此前发布正式回应，明确涉事电视广告从未公开播出，并下架相关播客节目，同时承诺实施强制高管培训、扩大推广审查规程及引入外部监管顾问审计等整改措施。市场在消化合规利空后，资金逢低回补推动股价盘中反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118254009","title":"异动解读｜ImmunityBio盘中下跌5.12%，FDA警告信持续压制市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1118254009","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118254009?lang=zh_cn&edition=full","pubTime":"2026-06-17 03:27","pubTimestamp":1781638038,"startTime":"0","endTime":"0","summary":"6月17日，ImmunityBio盘中下跌5.12%，报6.765美元/股，成交额6831.55万美元。消息面上，公司近期因核心药物Anktiva的营销合规问题收到FDA处方药推广办公室（OPDP）正式警告信，指出公司以误导性方式推广该IL-15受体激动剂药物，此前FDA已两度发出\"无标题信函\"提醒。尽管公司已作出澄清与整改回应，但合规风险叠加此前ASCO催化剂兑现后的获利了结压力，股价持续承压。公司当前PE为负值，尚处于亏损状态，市场对其商业化前景的信心受到冲击。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171611221","title":"异动解读｜ImmunityBio盘中上涨5.06%，ASCO临床数据与指南纳入催化股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1171611221","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171611221?lang=zh_cn&edition=full","pubTime":"2026-06-09 00:43","pubTimestamp":1780937020,"startTime":"0","endTime":"0","summary":"6月9日，ImmunityBio盘中上涨5.06%，报7.268美元/股，成交额4731.63万美元。该股此前因利好兑现遭获利了结，自5月下旬以来连续回调，本次反弹或与多项临床催化剂持续发酵有关。消息面上，公司近期在ASCO年会发布ANKTIVA在非小细胞肺癌及膀胱癌领域的最新III期临床数据；同时INBRX-106在一线头颈部鳞癌中期II期数据显示联合组客观缓解率达44.0%，显著优于对照组的21.4%。此外，CSCO尿路上皮癌诊疗指南已纳入ANKTIVA联合BCG作为新型保膀胱治疗手段，进一步夯实其商业化前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183934804","title":"异动解读｜ImmunityBio盘中下跌5.01%，利好兑现抛压持续发酵股价延续回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1183934804","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183934804?lang=zh_cn&edition=full","pubTime":"2026-06-06 01:51","pubTimestamp":1780681888,"startTime":"0","endTime":"0","summary":"6月6日，ImmunityBio盘中下跌5.01%，报6.925美元/股，成交额5331.82万美元。该股自5月下旬以来持续承压，延续多重利好兑现后的获利了结态势。消息面上，此前ImmunityBio密集释放催化剂，包括AUA临床疗效数据、ISPOR卫生经济学分析显示ANKTIVA联合BCG较TAR-200更具成本效益，以及竞争对手enGene关键临床数据失败带来的竞争格局利好。ImmunityBio是一家晚期免疫治疗公司，专注激活先天和适应性免疫系统治疗肿瘤及传染病，拥有自然杀伤细胞疗法、抗体细胞因子融合蛋白及疫苗载体综合平台。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138175163","title":"异动解读｜ImmunityBio盘中下跌5.12%，技术反弹后再度回落延续利好兑现抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1138175163","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138175163?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:21","pubTimestamp":1780064508,"startTime":"0","endTime":"0","summary":"5月29日，ImmunityBio盘中下跌5.12%，报7.325美元/股，成交额2761.04万美元。该股此前于5月21日及22日分别下跌7.89%和5.23%，5月26日曾借AUA积极疗效数据反弹5.66%，但未能延续升势，本次再度回落显示多重利好兑现后的获利了结压力尚未充分消化。消息面上，此前ImmunityBio密集释放催化剂，包括AUA临床疗效数据、ISPOR卫生经济学分析显示ANKTIVA联合BCG较TAR-200更具成本效益，以及竞争对手enGene关键临床数据失败带来的竞争格局利好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197561139","title":"异动解读｜ImmunityBio盘中上涨5.66%，AUA积极疗效数据支撑股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1197561139","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197561139?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:00","pubTimestamp":1779804047,"startTime":"0","endTime":"0","summary":"5月26日，ImmunityBio盘中上涨5.66%，报7.55美元/股，成交额2373.4万美元。此前该股在5月21日及22日分别下跌7.89%和5.23%，经历连续两日获利了结后，本次上涨呈现技术性反弹特征。前期利好兑现后的抛压消化后，市场对该临床数据的重新定价推动股价企稳回升。ImmunityBio是一家晚期免疫治疗公司，专注于激活先天和适应性免疫系统，拥有自然杀伤细胞疗法、抗体细胞因子融合蛋白及疫苗载体等综合平台，覆盖多种肿瘤类型和传染病的后期临床开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191196911","title":"异动解读｜ImmunityBio盘中下跌5.23%，多重利好兑现后延续回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1191196911","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191196911?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:05","pubTimestamp":1779458716,"startTime":"0","endTime":"0","summary":"5月22日，ImmunityBio盘中下跌5.23%，报7.335美元/股，成交额2022.58万美元。此前该股已于5月21日下跌7.89%，本轮回调延续获利了结态势。尽管基本面催化剂密集落地，但利好集中兑现后市场抛压显现，成交额较前一交易日明显缩量，显示卖盘力度有所减弱但多头承接意愿仍偏弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176140531","title":"异动解读｜ImmunityBio盘中下跌7.89%，多重利好释放后股价回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1176140531","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176140531?lang=zh_cn&edition=full","pubTime":"2026-05-21 23:01","pubTimestamp":1779375706,"startTime":"0","endTime":"0","summary":"5月21日，ImmunityBio盘中下跌7.89%，报7.418美元/股，成交额5214.07万美元。尽管基本面利好叠加，股价在催化剂集中兑现后出现回调，成交额放大显示市场存在获利了结压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167708101","title":"ImmunityBio公布Nai+BCG对比Nadofaragene与TAR-200在完全缓解率方面的积极疗效比较数据于AUA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1167708101","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167708101?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:33","pubTimestamp":1779190397,"startTime":"0","endTime":"0","summary":"ImmunityBio在2026年美国泌尿外科学会年会上，公布了其Nai联合BCG疗法，相较于Nadofaragene与TAR-200疗法，在完全缓解率方面展现出的积极疗效比较数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159036048","title":"ImmunityBio与日本BCG实验室达成独家美国协议，引进东京菌株以增强国内供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1159036048","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159036048?lang=zh_cn&edition=full","pubTime":"2026-05-17 01:36","pubTimestamp":1778952993,"startTime":"0","endTime":"0","summary":"ImmunityBio已与日本BCG实验室签署了一项独家美国协议，旨在引进东京菌株的BCG（卡介苗）。这一合作将显著增强美国境内的BCG供应稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144352518","title":"异动解读 | Q1每股亏损远超预期，ImmunityBio盘中大跌5.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144352518","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144352518?lang=zh_cn&edition=full","pubTime":"2026-05-12 01:31","pubTimestamp":1778520713,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.今日盘中大跌5.93%，引起了市场的广泛关注。消息面上，公司此前披露的第一季度业绩显示，尽管产品净收入达到4400万美元，超出了市场预期，但每股亏损高达0.62美元，远高于分析师预期的0.07美元，亏损幅度同比大幅扩大超过313%。虽然公司在营收端保持了近2.7倍的同比高速增长，但市场对其盈利能力的担忧持续发酵。投资者正在消化收入高增长与巨额亏损之间的矛盾，这导致了股价在经历前一交易日的反弹后出现显著回落。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunitybio.com","stockEarnings":[{"period":"1week","weight":-0.0364},{"period":"1month","weight":0.1119},{"period":"3month","weight":0.0905},{"period":"6month","weight":-0.083},{"period":"1year","weight":2.3403},{"period":"ytd","weight":3.0152}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.0107},{"period":"6month","weight":0.138},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ImmunityBio, Inc.于2002年10月7日在伊利诺伊州ZelleRx Corporation公司的名义下注册成立，于2010年1月22日，公司更名为Conkwest股份有限公司。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。公司是一家领先的临床剂型的现成自然杀伤细胞疗法生产商，记忆NK细胞，连同抗体细胞因子融合蛋白、白蛋白结合化学免疫调节剂和疫苗载体的综合平台。通过结合这些NK、巨噬细胞和T细胞激活平台，该公司相信ImmunityBio在免疫治疗领域处于领先地位，具有跨越多种肿瘤类型和传染病的后期临床开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.219152},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075725},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.095867},{"month":4,"riseRate":0.454545,"avgChangeRate":0.012919},{"month":5,"riseRate":0.454545,"avgChangeRate":0.054516},{"month":6,"riseRate":0.363636,"avgChangeRate":0.135253},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.043039},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.09189},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.03069},{"month":10,"riseRate":0.454545,"avgChangeRate":0.029893},{"month":11,"riseRate":0.636364,"avgChangeRate":0.121867},{"month":12,"riseRate":0.363636,"avgChangeRate":0.048951}],"exchange":"NASDAQ","name":"ImmunityBio, Inc.","nameEN":"ImmunityBio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ImmunityBio, Inc.,IBRX,ImmunityBio, Inc.股票,ImmunityBio, Inc.股票老虎,ImmunityBio, Inc.股票老虎国际,ImmunityBio, Inc.行情,ImmunityBio, Inc.股票行情,ImmunityBio, Inc.股价,ImmunityBio, Inc.股市,ImmunityBio, Inc.股票价格,ImmunityBio, Inc.股票交易,ImmunityBio, Inc.股票购买,ImmunityBio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}